<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97623">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02130557</url>
  </required_header>
  <id_info>
    <org_study_id>AV001</org_study_id>
    <nct_id>NCT02130557</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase (CP) Chronic Myelogenous Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avillion Development 1 Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avillion Development 1 Limited</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive
      bosutinib or imatinib for the duration of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be open for enrollment until the planned number of approximately 500
      Philadelphia Chromosome Positive (Ph+) patients have been randomized (approximately 250 Ph+
      patients in each treatment arm; a total of approximately 530 Ph+ and Ph- patients). All
      patients will be treated and/or followed for 5 years (240 weeks) after randomization until
      the study has closed. Patients who discontinue study therapy early due to disease
      progression or intolerance to study medication will continue to be followed yearly for
      survival for up to 5 years (240 weeks) after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare proportion of participants with Major Molecular Response (MMR) at 12 Months in the bosutinib arm with that of the imatinib arm</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>MMR is defined as &lt;0.1%Bcr-Abl1 on the International Scale (IS) by Real Time Quantitative Polymerase Chain Reaction (RT-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare proportion of participants with MMR at 18 Months in the bosutinib treatment group with the imatinib treatment group</measure>
    <time_frame>18 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the duration of MMR in the bosutinib treatment group with the imatinib treatment group</measure>
    <time_frame>5 Years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of MMR is measured only for participants who initially respond to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of participants with Complete Cytogenetic Response (CCyR) by 12 Months in both treatment groups</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CCyR is defined as absence of detectable Ph chromosomes in bone marrow aspirate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the duration of CCyR in both treatment groups</measure>
    <time_frame>5 Years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response is measured only for participants who initially respond to study medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive</condition>
  <arm_group>
    <arm_group_label>Bosutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosutinib, 400 mg, oral administration once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib, 400 mg, oral administration once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <arm_group_label>Bosutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <arm_group_label>Imatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Molecular diagnosis of CP CML of ≤ 6 months (from initial diagnosis).

          2. Adequate hepatic, renal and pancreatic function.

          3. Age ≥ 18 years.

        Exclusion Criteria:

          1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs),
             with the exception of hydroxyurea and/or anagrelide treatment.

          2. Any past or current Central Nervous System (CNS) involvement, including
             leptomeningeal leukemia.

          3. Extramedullary disease only.

          4. Major surgery or radiotherapy within 14 days of randomization.

          5. History of clinically significant or uncontrolled cardiac disease.

          6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic
             hepatitis B (hepatitis B surface-antigen positive), hepatitis C or evidence of
             decompensated liver disease or cirrhosis.

          7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease,
             Ulcerative Colitis, or prior total or partial gastrectomy.

          8. History of another malignancy within 5 years with the exception of basal cell
             carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered
             adequately treated and currently in complete remission for at least l2 months.

          9. Current, or recent (within 6 months), participation in other clinical trials.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Laurence Reilly, MBChB LLM</last_name>
    <email>Avillion@avillionllp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toronto, Ontario</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use central contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelogenous</keyword>
  <keyword>Chronic</keyword>
  <keyword>BCR-ABL Positive</keyword>
  <keyword>Bosutinib</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</keyword>
  <keyword>Philadelphia Chromosome</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Translocation, Genetic</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imatinib</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
